Thursday 16 October, 2025
Introduction: Tusamitamab ravtansine (Tusa Rav) is an antibody-drug conjugate targeted to carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), a cell-surface…
Read morePoster: Drug/Disease Modelling - Oncology
Semi mechanistic joint modeling of tumor dynamics and PFS in advanced breast cancer: leveraging data from early amcenestrant phase I-II trials
Thursday 16 October, 2025
Introduction: Amcenestrant is an orally bioavailable selective estrogen receptor (ER) degrader developed for the treatment of ER+/HER2- advanced breast cancer….
Read moreSemi-mechanistic pharmacokinetic-pharmacodynamic modeling of tumor size dynamics in advanced breast cancer patients treated with single-agent amcenestrant
Thursday 16 October, 2025
Introduction: Selective estrogen receptor degraders (SERDs) provide an important therapeutic option for hormone receptor positive breast cancer [1]. SERDs act…
Read moreSemi-physiological Pharmacokinetics of Bortezomib in Pediatric Patients with Acute Lymphoblastic Leukemia
Thursday 16 October, 2025
Objectives: Bortezomib is a proteasome inhibitor targeting the 20S proteasome used in the treatment of adult multiple myeloma, and is…
Read moreSemimechanistic clearance models of oncology monoclonal antibodies and impact of study design: cetuximab as a case study
Thursday 16 October, 2025
Objectives: Monoclonal antibodies (mAbs) undergo nonspecific linear and target-mediated nonlinear disposition, as well as recently described time-dependent elimination [1-4]. However,…
Read moreModel-informed noninferiority of cetuximab biweekly to weekly dosing regimen in metastatic colorectal cancer
Thursday 16 October, 2025
Objectives: Cetuximab is a monoclonal antibody that targets epidermal growth factor receptor (EGFR), approved in metastatic colorectal cancer (mCRC). Initially…
Read morePopulation pharmacokinetic modeling of cisplatin in patients with small cell lung cancer using informative priors
Thursday 16 October, 2025
Objectives: The small cell lung cancer (SCLC) is the most aggressive type of lung cancer and is diagnosed in around…
Read moreConditional overall survival (OS) simulations with a joint tumor size (TS)-OS model to support oncology development decision making
Thursday 16 October, 2025
Objectives: TS-OS models characterize the relationship between TS dynamics and OS in oncology [1,2] to support drug development decision making….
Read moreMiddle-out physiologically-based pharmacokinetic modeling to support pediatric dosing recommendation for alectinib, an ALK tyrosine kinase receptor inhibitor
Thursday 16 October, 2025
Objectives: The study aimed to establish pediatric dosing guidelines for alectinib, an ALK inhibitor used in adults with ALK-positive advanced…
Read morePopulation Pharmacokinetic Analysis of Elranatamab in Patients with Multiple Myeloma
Thursday 16 October, 2025
Introduction: PF-06863135 (Elranatamab) is a T-cell redirecting bispecific antibody targeting both B-cell Maturation Antigen (BCMA) and the T-cell co-receptor CD3. Elranatamab…
Read more